Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer.
Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter.
A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).
Researchers from Hainan Medical University and collaborators have demonstrated that PGE2-EP2/EP4-G α s-PKA signaling drove the expansion of immunosuppressive VSIG4-high macrophages and promoted immunotherapy resistance in colorectal cancer (CRC).
LTZ Therapeutics Inc.’s LTZ-232 has gained IND clearance from the FDA, enabling initiation of a phase I study in patients with advanced metastatic colorectal cancer and other solid tumors.
Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer’s top 10 medicines and vaccines, generating $1.94 billion in 2025.
Children’s Hospital of Fudan University, Sydney Children’s Hospital and the University of Sydney have jointly patented new antibody-drug conjugates comprising an antibody targeting GD2 ganglioside covalently linked to cytotoxic drugs potentially useful for the treatment of osteosarcoma.
RSS
